Unlike KRAS mutations that reflect tumor-intrinsic signaling or CA19–9 as a nonspecific secretory product, UBASH3B expression directly quantifies NK cell-mediated immunosuppression while predicting differential chemotherapy responses. The gene discussed is KRAS; the disease is neoplasm.